| Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats | |
| Liu, Na; Xu, Liuqing; Shi, Yingfeng; Fang, Lu; Gu, Hongwei; Wang, Hongrui; Ding, Xiaoqiang; Zhuang, Shougang | |
| 刊名 | ONCOTARGET
 |
| 2017 | |
| 卷号 | 8期号:20 |
| 关键词 | hyperuricemic nephropathy ERK1/2 TGF-beta/Smad signaling pathway urate transporters inflammation |
| ISSN号 | 1949-2553 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3615022 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Liu, Na,Xu, Liuqing,Shi, Yingfeng,et al. Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats[J]. ONCOTARGET,2017,8(20). |
| APA | Liu, Na.,Xu, Liuqing.,Shi, Yingfeng.,Fang, Lu.,Gu, Hongwei.,...&Zhuang, Shougang.(2017).Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.ONCOTARGET,8(20). |
| MLA | Liu, Na,et al."Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats".ONCOTARGET 8.20(2017). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论